Tuesday, the pharma secured an exclusive Chinese commercialization license for Sciwind Biosciences China-approved GLP-1 injection
This research was supported by internal grants for professional development and the Evan and Marcy Duff Professional Development Grant, both awarded by North Carolina Wesleyan University
Research assessing muscle and tendon healing reported increases in angiogenic markers such as VEGF, CD34, and factor VIII in injured tissue following peptide exposure [6]
Manufacturing Capacity and Supply Chain Investment: In a bid to avoid previous shortages of injectable GLP-1s, Eli Lilly has amassed a $1.5 billion pre-launch inventory of its oral weight loss drug orforglipron ahead of FDA decision expected in April 2026 [4]
It mimics the GLP-1 hormone, which regulates: Appetite (reduces hunger and cravings)
Eye-related side effects Eye-related side effects with Mounjaro are uncommon and mainly affect people with diabetes , particularly those with existing diabetic eye disease